Enanta Pharmaceuticals has been granted a patent for compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Formula (I) represents the compound at the core of the invention. GlobalData’s report on Enanta Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Enanta Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Enanta Pharmaceuticals's grant share as of May 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11993600B2) discloses a compound represented by Formula (I) and its various derivatives, along with pharmaceutically acceptable salts. The patent claims cover a range of compounds with specific structural features, including the presence of —CN as Q1 and hydrogen as R4. Additionally, the patent includes pharmaceutical compositions comprising the disclosed compound and methods for treating or preventing virus infections, specifically coronavirus infections such as 229E, NL63, OC43, HKU1, SARS-CoV-1, SARS-CoV-2, or MERS coronavirus.
Furthermore, the patent describes methods for inhibiting viral 3C protease or viral 3CL protease in a subject by administering the disclosed compound or its pharmaceutically acceptable salt. The methods also extend to treating respiratory disorders in subjects by administering the compound orally, subcutaneously, intravenously, or by inhalation. The patent provides a comprehensive coverage of the compound's potential applications in the field of antiviral treatments and respiratory disorder management, emphasizing the therapeutic efficacy of the disclosed compound in various medical conditions.
To know more about GlobalData’s detailed insights on Enanta Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
